<div id="readability-page-1"><p>Viking Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on May 1. Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on the stock and has a $107.00 price target.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Edward Nash has given his Buy rating due to a combination of factors, including Viking Therapeutics’ solid capital position and advancing clinical programs. Despite a larger‑than‑expected quarterly loss driven by elevated R&amp;D spending, the company still holds over $600M in cash, and management projects this cash runway will comfortably fund operations into 2028, even as investment in development remains high near term.</p> <p>Nash also highlights the strategic expansion of the Phase I maintenance-dosing study of VK2735, which has been broadened from four to eight treatment arms to generate more robust efficacy and safety data. He views this trial modification as an important value driver for the pipeline and, coupled with the company’s strengthened financial visibility, supports maintaining a Buy rating and an unchanged $107 price target for VKTX shares.</p> <p>In another report released on May 1, BTIG also reiterated a Buy rating on the stock with a $125.00 price target.</p></div>

VKTX

ARKG

<p>Analyst Edward Nash from Canaccord Genuity has maintained a Buy rating on Viking Therapeutics with a price target of $107. Despite a larger-than-expected quarterly loss due to high R&D spending, the company has over $600M in cash, ensuring operations are funded into 2028. Nash highlights the expansion of the VK2735 study as a key value driver. BTIG also reiterated a Buy rating with a $125 price target.</p>

Tip Ranks

Viking Therap

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares Biotechnology ETF

SPDR S&P Biotech

Nash Maintains Buy on Viking Therapeutics, Keeps $107 Price Target Unchanged Amid Strong Cash Runway and Expanded VK2735 Study